Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Appointment of Nominated Adviser

16th Jan 2014 14:15

RNS Number : 8488X
Beximco Pharmaceuticals Ltd
16 January 2014
 



16 January 2014

BEXIMCO PHARMACEUTICALS LTD.

Appointment of Nominated Adviser

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, is pleased to announce that Daniel Stewart & Company plc ("Daniel Stewart") has been appointed as Nominated Adviser to the Company with immediate effect. Daniel Stewart will continue to act as the Company's Sole Broker.

 

 

For further information please visit www.beximco-pharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel: +880 2 8618220-1, Ext 10140

 

Daniel Stewart & Company

Paul Shackleton

James Thomas

Tel: +44 (0)20 7776 6550

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 7269 7169

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPBFMITMBMBBFI

Related Shares:

Beximco Pharma
FTSE 100 Latest
Value7,751.78
Change-158.75